SOURCE: Targeted Genetics Corporation

October 31, 2006 07:30 ET

Targeted Genetics to Present at the Rodman & Renshaw 8th Annual Healthcare Conference

SEATTLE, WA -- (MARKET WIRE) -- October 31, 2006 -- Targeted Genetics Corporation (NASDAQ: TGEN) will present at the Rodman & Renshaw 8th Annual Healthcare Conference, Tuesday, November 7, at 12:25 p.m. Eastern Time. H. Stewart Parker, President and Chief Executive Officer, will provide a corporate overview, including an update to the Company's lead product development program for inflammatory arthritis and other corporate activities. The conference is being held at the New York Palace.

To access the live audio webcast for this conference, please log on to Targeted Genetics' website at www.targetedgenetics.com to register and download any necessary software. The audio presentation and slideshow will be available for replay following the event. Additional information about the BIO Investor Forum can be found at http://investorforum.bio.org.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure, Huntington's disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website at www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our business strategy, our product development and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to raise capital when needed, the timing, enrollment of patients, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, and our ability to obtain, maintain and protect our intellectual property, as well as other risk factors described in Item 1A. Risk Factors in our reports on Form 10-K and Form 10-Q that we file with the securities and exchange commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Contact Information

  • Investor and Media Contact:
    Stacie D. Byars
    Director, Communications
    Targeted Genetics Corporation
    (206) 521-7392